Among the genes contained in the signature, ZIC2, which is robustly selected in each bootstrap of the CIMP prediction task and is significantly more expressed in CIMP-positive tumors for each tissue, has been known to act as a Wnt/ β-catenin signalling inhibitor [48] which is usually upregulated in several cancers. This evidence concerns the gene ZIC2 and cancer.